VKH
NBIX icon

Virtu KCG Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Virtu KCG Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$238K Sell
5,174
-7,692
-60% -$373K 0.01% 1961
2017
Q1 		$557K Sell
12,866
-14,358
-53% -$615K 0.02% 1259
2016
Q4 		$1.05M Buy
27,224
+7,427
+38% +$336K 0.03% 726
2016
Q3 		$1M Buy
+19,797
New +$986K 0.02% 701
2015
Q4 		– Sell
-12,592
Closed -$501K – 3783
2015
Q3 		$501K Buy
+12,592
New +$609K 0.01% 1523

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtu KCG Holdings's NBIX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Neurocrine Biosciences (NBIX) stake by 60% in Q2 2017, selling an estimated $373K and leaving 5,174 shares worth $238K. The position accounts for 0.01% of the portfolio, ranked #1961.

Virtu KCG Holdings first reported a position in NBIX in Q3 2015 and has held it in 5 quarters since. The position peaked at $1.05M in Q4 2016. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

  • Virtu KCG Holdings held 5,174 shares of Neurocrine Biosciences worth $238K as of Q2 2017.
  • Virtu KCG Holdings sold 7,692 Neurocrine Biosciences shares in Q2 2017, an estimated $373K.
  • Neurocrine Biosciences made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1961 holding.
  • Virtu KCG Holdings first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 5 quarters since.
  • Virtu KCG Holdings's Neurocrine Biosciences position peaked at $1.05M in Q4 2016.
  • 221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.